SUSTAINABILITY REPORT 2020 - Zuellig Pharma
SUSTAINABILITYREPORT2020
CONTENTSMESSAGEFROMOUR CEOp4JOINING THEFIGHT ENTp33RESPECTINGTHEENVIRONMENTp44SETTING THEHIGHESTSTANDARDS OFINTEGRITYp50ON THE COVERThe cover illustration brings to lifeZuellig Pharma’s sustainability visionof building a healthier future forAsia. It incorporates our sustainabilitypillars of Nurturing Talent andGRICONTENTINDEXp59Respecting the Environmentcentred around Improving HealthOutcomes, with the two handsrepresenting the trust that ourstakeholders put in us in Setting theHighest Standards of Integrity.
ABOUTTHISREPORTMaking healthcare more accessible has underpinned ZuelligPharma’s business throughout our hundred-year history. We seekto make sustainability an integral part of how we work towardsour vision of building a healthier future for Asia.This first sustainability report reflects our commitment tooperating with the mindset of long-term value creation and withaccountability, as we embark on this sustainability journey inpartnership with our clients, customers, suppliers and partners.BOUNDARY AND SCOPEREPORTING APPROACH102-46, 102-50, 102-51, 102- 52AND FRAMEWORK102-54, 102-56The information containedin this report pertains to theThis report has been preparedperiod January 1 to Decemberin accordance with the Global31, 2020 and covers ZuelligReporting Initiative (GRI)Pharma’s operations across 13Standards: Core option. A GRImarkets. Where performanceContent Index detailing thedata for Q4 2020 is not yetspecific standards appliedavailable, we have stated soand disclosures reportedaccordingly and will updateis available on our website,the full-year figure in our 2021please refer to page 59 ofsustainability report.this report.We intend to publish our102-53The data included insustainability report on anthis report has undergone aannual basis moving forwardrigorous internal review. WeWe value opinions from internalto hold ourselves accountablehave not sought externaland external stakeholders to helpto our commitments, chart ourassurance for this inauguralus improve and progress in ourprogress, and identify areas inreport but plan to do so inapproach to sustainability andwhere we can improve.future reports.sustainability communications.Please send your feedback to:Zuellig Pharma Sustainability Teamsustainability@zuelligpharma.com
MESSAGEFROMOUR CEO102-14Dear stakeholders,I am pleased to present to you our first SustainabilityHaving joined the United Nations Global Compact inReport, which aims to capture sustainability in action at2019, we continue to build on our commitment to supportZuellig Pharma and communicate how we are integratingthe sustainable development agenda and actively worksustainability into our business.towards our vision of building a healthier future for Asia.2020 has challenged the world in myriad ways, and theIt has truly been a year of impact amidst theimpact of COVID-19 has been felt in all the communitieschallenging times. We achieved the EcoVadis Silverthat we serve. I stepped into my new role as CEO duringMedal 2020 for our sustainability efforts, placing us amongthis unprecedented time when our mission of makingthe top 3% of companies in our industry assessed by thehealthcare more accessible was more pressing than ever.sustainability ratings specialist. We also embarked on anWhat was most heartening for me was witnessing the spiritexercise to assess our carbon footprint and examine howand tenacity of our Zuellig Pharma employees and theirwe can reduce carbon emissions within our operations.daily commitment to living out this focused purpose.As one of the largest healthcare services providers inThis has also been a year of firsts: Our inauguralSustainability Month in November saw over 7,000Asia, we partnered with governments to ensure unhinderedemployees celebrate sustainability in action byaccess to critical medicines for over 350,000 hospitals,participating in future-focused activities around eachclinics and medical centres that we serve across our 13sustainability pillar. These were reinforced by Worldmarkets as they battled the pandemic. Beyond maintainingQuality Day and Safety Week initiatives which united oursupply chain continuity, our priority was in ensuring theworkforce behind these two important material issues. Wehealth and safety of our 12,000 employees, especiallyalso welcomed the active involvement of our suppliersour frontline staff who worked tirelessly to fulfil criticalin our first-ever Supplier Sustainability Awards held inoperations roles.conjunction with Sustainability Month. Our people areAs we continue in the global fight against COVID-19,sustainability remains paramount to Zuellig Pharma.We will uphold the principle of sustainability inconsidering positive outcomes for futuregenerations while meeting immediatestakeholder needs. We have laid a firmfoundation with the developmentof a sustainability framework thatoutlines four key impact pillars.the heart of Zuellig Pharma, and I am glad to witness animmense passion and enthusiasm for sustainability withinthe organisation.As we look back on the year, we take away lessons forthe future but also remember how we stood strong as one#ZPUnited. I am immensely proud of the progress made,which would not be possible without our employees,clients, customers, suppliers and partners workingalongside us to build a healthier future for the region.Launching this report is a significant milestonefor us. I hope it provides you with a glimpse into#SustainabilityInAction at Zuellig Pharma and anunderstanding of our deep commitment to makingJOHN GRAHAMCHIEF EXECUTIVE OFFICERZUELLIG PHARMAhealthcare more accessible in Asia for the long-haul.I look forward to your continued partnership as wepersevere on our sustainability journey.4
JOINING THE FIGHTAGAINST COVID-19The global COVID-19 crisis has brought about significant disruption around the world. It has been more important than everfor us to ensure that essential medicines continue to be available to those who need them most. At the same time, the healthand safety of our people and communities are of utmost priority as we continue to fulfil our mission of making healthcaremore accessible during the pandemic.PREVENTING A LOGISTICALL O C K D O W N T O O U R S U P P LY C H A I NDrivingdigitalsolutionsEnforcing stringenton-groundimplementationMaintainingongoing dialoguewith governmentsWorking with governments andhealthcare associations across the regionhas always been an integral part of ourbusiness. During this unprecedentedtime, it has been an even bigger priorityto ensure the continued movement ofcritical medical supplies by maintaining anongoing dialogue and close cooperationwith relevant authorities.In the face of lockdowns, we obtainedexemption letters from governmentsto allow freedom of movement forour frontline employees and transportpartners across checkpoints andprovincial borders. This ensured that allland deliveries of essential medicines andhealthcare supplies continued.In geographically complex countries,we faced additional challenges like thesuspension of domestic passenger flights.In the Philippines, we tackled the issue byworking with the Philippine Air Force tocharter flights to transport medication tothe Visayas and Mindanao regions.S U S TA I N A B I L I T Y R E P O R T 2 0 2 0During this time, we expeditedthe launch of digital solutions likeeZRx in several markets to enableour customers to place orders forprescription drugs, medical devices,or consumer health products virtually— anytime, anywhere.To improve access to healthservices, we worked closely withlocal health authorities and doctorassociations to launch eZConsult,a telemedicine application, to servethe large numbers of peopleseeking medical consultation onlineamidst lockdowns and socialdistancing measures.Our data analytics team andwholly-owned subsidiary Klinify havealso added several features to providereal-time insights about COVID-19trends, helping doctors, customers andclients to improve patient outcomes.Since the early onset of thepandemic, we have been firmlycommitted to preventing disruptionsto the supply chains, while takingprecautionary measures to protectour teams. Our Business ContinuityPlans have been tested in real timeand have held up well.In Taiwan, our team workedclosely with the Taiwan Centerfor Disease Control, and inMalaysia with Ministry of Health,to implement measures thatminimise the risk of virustransmission within our premises.This includes comprehensive safedistancing measures and regularcommunication with employees toensure compliance.5
PROTECTING AND CARINGFOR OUR PEOPLEThe safety and wellbeing of our employees is our highest priority, and we launched numerous initiativesacross our markets to help our employees feel secure and productive as they continue working to makehealthcare more accessible. Frequent updates were sent to employees from senior management assuringthem of company support and policies to safeguard health and wellbeing.A company-wide #ZPUnitedmovement was launched torecognise and encourageemployees. Client appreciationnotes were also shared with eachcountry team.INDONESIAH O N G KO N G & M ACAUWeekly updates with tips onhow to work or learn from homeand stay safe while commutingto workProvision of care packages to allemployees including vitamin Ctablets, fruits, surgical mask andhand sanitisersThe #ZPUnited campaign sawover 100 posts within a week oninternal social platformsKO R E ASINGAPOREPersonalised message on theCOVID-19 situation was sentto each employee, with anemergency mobile contact linebeing made available for issuesor questionsWhatsApp broadcast channel setup to allow employees to receivetimely updates, especially forthose with no convenient accessto emailsA #ZPUnited in Action employeevolunteer taskforce to supportcolleagues with mission-criticalactivities attracted over 2,000volunteersSUPPORTING LOCAL COMMUNITIESWe also sought to support frontline efforts and the communities in which we operate.In Thailand, we provided free delivery and distribution of COVID-19 treatment medications to the Departmentof Medical Services and hospitals within the nation-wide network of the Ministry of Public Health.In the Philippines, we launched Project Kaagapay with our partners, MDI, Go Negosyo and ABS-CBN, toprovide personal protective equipment (PPE) for hospitals and ventilators for COVID-19 referral hospitals.With donations from Zuellig Pharma and individual contributions from employees, our Myanmar teamdonated 800 sets of PPE and a significant amount of medical supplies to Myanmar’s Containment andEmergency Response COVID-19 Committee and various medical institutions.Much has happened and continues to unfold. We are proud that as #ZPUnited, we have adaptedremarkably well in the face of change and challenges, and can only grow stronger together.S U S TA I N A B I L I T Y R E P O R T 2 0 2 06
HIGHLIGHTSO F T H E ofYEARHighlightstheYearImproving Health Outcomes131 76,000Patient AccessProgrammes forpatients supported throughour Affordability Programmes229,768Withpatients USD2.3 million 2,000,000vaccine dosesadministered at eventsacross the regionsince Zuellig Pharmabegan operationsworth of redemptions formedicationImproved health literacy for 485,000peopleEngaged 40,000healthcare professionalsthrough198diseaseawarenessprogrammes 86,000healthcare rammesto better serve their patients withthe adoption of digital solutionslike eZRx and eZConsultNurturing Talent40Providingemployment for12,029people in13 marketsgraduates fromregional talent developmentprogrammes340,806hours in staff training todevelop skills andcompetenciesZerofatalities as a result ofwork-related injury 7,000employees engaged throughactivities in our inauguralSustainability MonthS U S TA I N A B I L I T Y R E P O R T 2 0 2 0 600employees attended our firstSafety Week virtual event to learnabout workplace health & safety7
HIGHLIGHTSOF THE YEARRespecting the Environment1.9M kWh3Rin energy savings from energyefficiency and other electricityreduction initiatives(excluding solar energy)Reduce-Reuse-Recycleprogrammes implemented inall our 13 markets to aim for10%yearly reduction inpackaging waste2M kWhgenerated through pilotsolar panels to power ourown operations in Taiwanand Vietnam27operational locationsreinforced with climaterisk mitigation measuresunits of our innovativecold-chain solutioneZCooler deployed acrossAsia to protect integrityof tting the Highest Standards of IntegrityD BY-tecEREPOWva-Q636,000downloads of our eZTrackerapp to help improve supplychain traceability and fightcounterfeit drugsS U S TA I N A B I L I T Y R E P O R T 2 0 2 0operational sites certified by TAPA (TransportedAsset Protection Association) assuring thesecurity of our logistics supply chain.Communicated to 12,000employees on anti-corruptionpolicies and procedures8
ABOUTZUELLIGPHARMA102-1, 102-2, 102-3, 102-4, 102-5, 102-6, 102-7Zuellig Pharma is one of the largest healthcare services groups in Asiaand is part of the Zuellig Group, a privately-owned company. We areheadquartered in Singapore.The company was started almost a hundred years ago and has grown tobecome a US 13 billion business covering 13 markets with over 12,000employees. We serve over 350,000 medical facilities and work with over500 clients, including the top 20 pharmaceutical companies in the world.S U S TA I N A B I L I T Y R E P O R T 2 0 2 09
ABOUT ZUELLIG PHARMAOur focus in Asia since the beginning makes us familiar with itsdiverse cultures and needs, and how the healthcare environmentis evolving. We recently launched the Zuellig Health SolutionsInnovation Centre to develop new services and address pressinghealthcare needs in Asia. These enable us to provide a suite ofbusiness solutions and services to support the growing healthcareneeds in this region. They cover distribution, digital, commercial,clinical reach, patient care and payor services.DISTRIBUTI ON &CLIENT SERVICESZPTHERAPEUTI CSC A R ECONN ECTMedical DevicesDiabetes / SpecialtyConsumer HealthCLIN ICALREACHD IG ITA LDATAANALY TICSIMP ROVINGHEA LTHO UTCOMESN URT UR I N GTA L E N TR E S PECT IN G T HEE N V IR ONME N TSU STA IN AB I LI T YSET TING THEHIGH EST STA NDA RDSO F INTEGRITYS U S TA I N A B I L I T Y R E P O R T 2 0 2 010
ABOUT ZUELLIG PHARMAOUR SERVICESDISTRIBUTIONPATIENT CAREPAYOR SERVICESOur end-to end solutions andextensive distribution networkprovides access to all relevantchannels in even the mostremote areas of AsiaWe provide innovative healthcaresolutions that encouragehealthier lifestyles, driveprescription adherence andimprove health outcomesOur payor services helpcompanies and insurers developplans and programmes to deliverhigh quality healthcare whileminimising administrative workand managing cost TransportationPick & Pack Patient Education & PublicWarehousingRedressingCold Chain Solutions AwarenessAffordability SolutionsDisease Management & Patient Engagement ProgrammesMass VaccinationsZP THERAPEUTICSWe aim to be the go-tocommercialisation partner forthe healthcare industry throughproviding best-in-class, life-cyclemanagement of commercialsolutions to create outcomes thattransform patient journeys and thehealthcare industry Marketing ExcellenceMedical AffairsAlliance ManagementDigital TechnologyRegulatory AffairsSales ExcellenceS U S TA I N A B I L I T Y R E P O R T 2 0 2 0 AdministrationCost ManagementSolutions and InterventionsData Insights and AdvisoryDATA ANALYTICSCLINICAL REACHThrough our analytics, we help todeliver targeted insights to drivegrowth and performance in keytherapeutic areasWe provide end-to-end clinicalsupply chain solutions to ensureclinical trials and research runsmoothly Market IntelligenceAnalytics Advisory Clinical Research Planning& DesignClinical Trial Supplies& LogisticsClinical Research TechnologySolutionsClinical Research Compliance& Quality Management11
ABOUT ZUELLIG PHARMAOUR MISSIONIntegrity& TrustA N D C O R E VA L U E S102-16BUILD OPEN HONESTRELATIONSHIPSBeing true to our mission of Making HealthcareCollaborationMore Accessible has led us to where we are todayBUILD PARTNERSHIPSINTERNALLY AND EXTERNALLYand will continue to guide us in our growth.InnovationOur Core Values are the driving force behind whoBE CREATIVE ANDOPEN-MINDEDwe are and what we do. They inspire us to alwaysPassion forExcellenceput the needs and wellbeing of the people andcommunities we serve first.BE DETERMINED TODELIVER ONLY THE BESTPersonalGrowthVA L U E C H A I N O FOUR BUSINESSPURSUE PROGRESSAND LEARNING102-9At Zuellig Pharma, our unique position in thehealthcare ecosystem allows us to connect clients,customers and patients across the value chain.PAYOR SERVICESPAYOR SERVICESPAYOR SERVICESCARECONNECTCARECONNECTCARECONNECTCLINICAL REACHCLINICALZPREACHCLINICALTHERAPEUTICSREACHZP DISTRIBUTIONCHANNEL CHANNEL CHANNELPATIENTCAREPATIENTCAREPATIENTCARES U S TA I N A B I L I T Y R E P O R T 2 0 2 012
ABOUT ZUELLIG PHARMAOUR MEMBERSHIPSA N D A S S O C I AT I O N S102-12, 102-13We joined the UnitedWe are part of the BSRWe are a member ofZuellig Pharma receivedNations Global CompactHealthcare WorkingGreen Freight Asia, aa Silver medal fromin 2019 to bring to lifeGroup. BSR is a globalnon-profit associationsustainability ratingsour sustainability visionnon-profit organisationof industry players whospecialist EcoVadis forof building a healthierworking to build acollaborate with otherour commitment tofuture for Asia andjust and sustainablecompanies, NGOs, anddriving sustainabilityfulfil our mission ofworld. We contributegovernments to improvewithin our business. Thismaking healthcare moreto develop researchenergy efficiency, fuelranks Zuellig Pharmaaccessible. We are firmlyand resources that helpefficiency, reduce carbonamong the top 25% of allcommitted to supportingovercome the majoremissions, and to lowercompanies assessed bythe Global Compact andchallenges to reducingoperational costs acrossEcoVadis, and within theimplementing its Tenthe burden of diseasethe entire supply chain.top 3% of its industry.Principles across ourand improving globalTo signify our deep13 markets.health outcomes.commitment to furtheringenergy efficiency in theCLICK HERE TOREAD OUR LATESTCOMMUNICATIONON PROGRESS.S U S TA I N A B I L I T Y R E P O R T 2 0 2 0industry, we have alsojoined Green Freight Asia’sBoard of Directors.13
S U S TA I N A B I L I T YAT Z U E L L I GPHARMAAs a leading healthcare service provider in Asia, we play an important role inmaking healthcare more accessible. This enduring purpose has underpinnedour business throughout Zuellig Pharma’s hundred-year history and shapeda consistent approach of looking beyond immediate needs to consider thelong-term future of our key stakeholders.S U S TA I N A B I L I T Y R E P O R T 2 0 2 014
S U S TA I N A B I L I T Y AT Z U E L L I G P H A R M AIn 2019, we embarked on a journey to formally embed this philosophy into our business and make sustainabilityan integral part of our long-term strategy with the development of a sustainability framework. As 2020 unfoldedin unprecedented and unpredictable ways, our sustainability vision to build a healthier future for Asia has neverbeen more important.Working towards this vision, we identified 22 material sustainability issues on which we have significantenvironmental, social and economic impact. These material issues sit under four sustainability pillars whichdefine what sustainability means to us. They form the foundation and focus of our efforts to drive long-termvalue for the business and our stakeholders.ZUELLIG PHARMAS U S TA I N A B I L I T Y F R A M E W O R KPURPOSESUSTAINABILITY VISIONMaking HealthcareMore AccessibleBuilding a healthier future for Asia with ourClients & CustomersImprovingHealth OutcomesNurturingTalent Access to Healthcare Talent Recruitment,Development & Retention Affordability Community Engagement Preventative Care Enabling HealthcareProfessionals Workplace Health & Safety Employee Wellbeing Employee Engagement Diversity & InclusionRespectingThe Environment Climate Resilience Climate Change Mitigation& Energy Efficiency Responsible WasteManagement Environment ComplianceSetting The Highest Standards Of IntegrityS U S TA I N A B I L I T Y R E P O R T 2 0 2 0 Product Quality & Security Data Privacy & Security Counterfeit Products Public Policy Parallel Trade Responsible Sourcing Bribery & Corruption Responsible Sales& Marketing15
S U S TA I N A B I L I T Y AT Z U E L L I G P H A R M AM AT E R I A L I T Y A S S E S S M E N TWe undertook a comprehensive process of identifying and assessing our material sustainability issues, as thebasis to developing our sustainability framework.As part of this process, we conducted 45 interviews with key internal and external stakeholders tounderstand their perspectives on the sustainability topics where Zuellig Pharma has the most significantimpact, and which substantively influence our business and stakeholders. The results informed our approachto managing and reporting on sustainability. The materiality process comprised the following stages:CONTEXTSETTINGA benchmarkinganalysis wasconductedto identifysustainabilityissues in theindustry and peerapproaches tosustainability.INTERVIEWSConductedinterviewswith internaland externalstakeholders togather furtherinsights into thesustainabilitycontext of ZuelligPharma.ANALYSIS &VALIDATIONFindings fromprevious stageswere analysedand presented toCEO and ExecutiveManagement tofinalise the list of22 sustainabilityissues.To ensure we remain relevant and are awareof any shift in importance of the current list oftopics, we will conduct a light-touch review of ourmaterial topics each year, with more comprehensiveassessments undertaken every few years.S U S TA I N A B I L I T Y R E P O R T 2 0 2 016
S U S TA I N A B I L I T Y AT Z U E L L I G P H A R M AO U R M AT E R I A LS U S TA I N A B I L I T Y T O P I C S102-46, 102-47ACCESS TO HEALTHCAREAFFORDABILITYEnable access to medicinesthrough: Warehousing and logisticsservices to ensuregeographical access,including innovative lastmile solutions that bringvital medicines to remotepopulations Digital solutions that unlockgreater efficiency and reachfor healthcare professionals Registration andcommercialisation ofproducts not otherwiseavailable in countriesReduce overall cost ofhealthcare by: Minimising abuses and costleakage across the supplychain Promoting patient adherenceand disease management Providing patient assistanceand instalment programmesPREVENTATIVE CAREIncrease disease awareness,support access to vaccines andpreventative healthcare services.TALENT RECRUITMENT, DEVELOPMENT & RETENTIONNurture talents by recruiting the right individuals and developing themto reach their best potential.WORKPLACE HEALTHAND SAFETYEMPLOYEE WELLBEINGPromote physical and mentalCreate a safe workingenvironment for all employeesthrough: Implementing and enforcingproper safety training andeducation Upholding highest standardsof operational excellence infacilities and officesCLIMATE RESILIENCEIdentify and mitigate risks to ourfacilities, so that our business canprepare for and recover quicklyfrom climate impacts.S U S TA I N A B I L I T Y R E P O R T 2 0 2 0wellbeing of all employees.EMPLOYEE ENGAGEMENTBuilding personalisedapproaches to developingfulfilling careers for our team,supported by competitive payand managerial support.COMMUNITY ENGAGEMENTImproving health outcomesof the communities weoperate in by: Engaging our employeesand local communitiesaround sustainable healthybehaviours and access tohealthcareENABLING HEALTHCAREPROFESSIONALSProvide medical advancementto the healthcare communityand expanding accessto patients through ZPTherapeutics’ innovativesolutions and services, enrichedby a deep understanding of thehealthcare industry.DIVERSITY ANDINCLUSIONCreate an inclusive workplacethat promotes equal opportunityand is free from discriminationand harassment, so thatemployees can realise theirfull potential regardless of age,gender, ethnicity, ability, sexualorientation and gender.ENVIRONMENTAL COMPLIANCEOperate in an environmentally conscious way according toenvironmental laws and regulations of our markets, while striving toalign with international best practices and guidelines.17
S U S TA I N A B I L I T Y AT Z U E L L I G P H A R M AO U R M AT E R I A LS U S TA I N A B I L I T Y T O P I C S ( C O N T. )CLIMATE CHANGE MITIGATION AND ENERGY EFFICIENCYReduce carbon emissions through: Measure: Collect baseline data aligned with international standards Manage: Use renewable energy and technology in offices, facilities,fleet & equipment Mitigate: Encourage employee and local community activities thathelp reduce or offset emissionsPRODUCT QUALITYAND SECURITYEnsure product integrity, productsecurity, patient safety and avibrant culture of quality.BRIBERY ANDCORRUPTIONPrevent bribery and corruption,ensuring we conduct ourbusiness in the highest ethicalstandards.COUNTERFEIT PRODUCTS& PARALLEL TRADERoll out eZTracker solutionto empower all parties inthe healthcare ecosystem(including patients) to detectand fight counterfeit productsand parallel trade.S U S TA I N A B I L I T Y R E P O R T 2 0 2 0RESPONSIBLE WASTEMANAGEMENTReduce and manage: Waste within facilitiesand officesDATA PRIVACY AND SECURITYProtect client, customer and patient data by continually developingrobust cybersecurity and data privacy programmes to respond to anever-evolving landscape.RESPONSIBLE SOURCINGPUBLIC POLICYEngagement with our suppliersto institute, monitor and improvesustainable procurementpractices that have a positiveenvironment, social andeconomic impact acrossthe purchasing and supplymanagement lifecycle, whilstupholding company needs forcost efficiency and security ofcritical supply. These includeaddressing environmentalchallenges, promoting fairlabour practices and partneringfor innovation.Support governments inbuilding a healthier future forcommunities through healthcarereform, healthcare financing andsupport, disease management,and the use of data analytics toguide policy.RESPONSIBLE SALESAND MARKETINGEnable patients to make informeddecisions on medicine usage.18
S U S TA I N A B I L I T YGOVERNANCEPOLICY102-18, 102-20Driving sustainability throughout the organisationThe Zuellig Pharma Sustainability Policy wasrequires strong leadership support. This is why weestablished in 2020 to communicate our vision andhave set up a governance structure with our Boardkey sustainability commitments. It serves as anof Directors, CEO and executive management teamoverarching policy that encompasses sustainability-steering our sustainability agenda. Each of our keyrelated policies in the areas of Environment, Social,pillars and material issues is owned by a member ofGovernance and reflects our sustainability prioritiesour executive or senior management team.based on our four pillars.Pillar heads drive progress and execution ofDETAILS OFOUR POLICYCOMMITMENTS CANBE FOUND HERE.pillar projects across markets and ensure issueowner accountability. Issue owners serve as subjectmatter experts to track and share relevant externaldevelopments around thematerial issues, and outlineroadmaps to achievedesired goals for the pillar.Board of DirectorsAn established network ofmanagement officers providessupport and coordination onlocal activities.LEADERSHIPregional and country projectCEOSustainability Steering Committee(Executive Management Team & Area Directors)4 Pillar Leads22 Issue Owners4 Area DirectorsRegional Project Management OfficerSUPPORTIMPLEMENTATIONS U S TA I N A B I L I T Y AT Z U E L L I G P H A R M AS U S TA I N A B I L I T Y13 Country GMsCountry Project Management Officer52 Country Pillar LeadsS U S TA I N A B I L I T Y R E P O R T 2 0 2 019
S U S TA I N A B I L I T Y AT Z U E L L I G P H A R M AS TA K E H O L D E R E N G A G E M E N T102-40, 102-42, 102- 43, 102-44An important aspect of our approach to sustainability is engaging our stakeholders openly and regularly, tounderstand and respond to their concerns, as well as to obtain their opinions and feedback to help us improve ourpractices and performance.Our key stakeholders are identified based on their influence on and relevance to Zuellig Pharma, as well asour impact on them. The table below summarises some of the key engagements that took place during the yearto address topics of interest, including formal and informal engagements that occur as part of our daily work:STAKEHOLDER GROUPCLIENTSKEY TOPICS OF INTERESTGeneral sustainability progressOUR RESPONSE HEALTHCARE COMPANIESEngagement Method andFrequency One-on-one communicationfrom client development teamthrough emails, meetings, etc.(Regular) Digital Magazine (Regularlyupdated here) LinkedIn and website newsupdates (Regular) Developed Sustainability Policyto provide an overview of ourapproach to sustainabilityDeveloped GRI-alignedsustainability report 2020 and UNCommunication on ProgressProvided information throughsustainability brochure andEcoVadis rating reportRespecting the Environment Pillar Climate Resilience Climate Change Mitigation &Energy Efficiency Responsible Waste Management Environmental Compliance Developed GHG PolicyImproving Health Outcomes Pillar Access to Healthcare, particularlyduring COVID-19 Community Engagement Affordability Preventative Care Enabling Healthcare Professionals Regular COVID-19 operationalstatus updates to clients fromclient development teamOngoing partnershipsIntegrity Pillar Product Quality & Security Data Privacy & Security Anti-Bribery & Corruption Responsible Sourcing Counterfeit Products & ParallelTradeResponsible Sales & Marketing Public Policy Communicated our polic
approach to sustainability and sustainability communications. Please send your feedback to: Zuellig Pharma Sustainability Team sustainability@zuelligpharma.com BOUNDARY AND SCOPE The information contained in this report pertains to the period January 1 to December 31, 2020 and covers Zuellig Pharma's operations across 13 markets. Where .
Smart Pharma Consulting. 1, rue Houdart de Lamotte - 75015 Paris - France Tel.: 33 6 11 96 33 78 E-mail: jmpeny@smart-pharma.com Website: www.smart-pharma.com. Consulting company dedicated to Strategy, Management and Organization services in the pharmaceutical sector. Smart Pharma Consulting. Core capabilities. 1. Strategy
N4 Pharma Plc Nigel Theobald, CEO Via Scott PR Allenby Capital Limited James Reeve/Asha Chotai Tel: 44 (0)203 328 5656 Scott PR Georgia Smith Tel: 44 (0)1477 539 539 About N4 Pharma N4 Pharma is a specialist pharma
Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the
McKinsey & Company report that 66% of pharma product launches between 2003 and 2009 performed below forecast4. However, pharma is not the only industry facing increasing launch challenges. Consumer product launches experience many hurdles also common to pharma. A 2014 global study by Simon Kucher & Partners revealed that, across all major
Goerlich Pharma International GmbH Am Gewerbering 4/6 83533 Edling / Germany Tel.: 49-(0)8071-9083-0 Fax: 49-(0)8071-9083-29 e-Mail: sales@goerlich-pharma.com www.goerlich-pharma.com ARCO // COMPANY 1959 Gründung der A.R.C.O. -Chemie GmbH durch Arthur Loose und Cornelius Souv
Dow Corning 5 Simethicone and Emulsion 5 . 12.500 cSt Zinc Oxide Pharma 4 API Zinc Oxide Pharma 6 API Zinc Oxide Pharma 8 API . Q7-9120 Silicone Fluid 20 cSt 100 cSt 350 cSt 1.000 cSt 12.500 cSt ST-Dimethiconol 40 Q7-9180 Silicone Fluid 0,65 cSt 1 cSt ST-Cyclomethicone 5-NF ST-Cyclomethicone 56-NF
The robot can successfully process multiple PDFs with 100% accuracy and create a POI (purchase order interface) file that is processed in SAP which creates the sales orders. In 3 months, the robot processed 6K PDF pur
Animal nutrition has pronounced direct impact not only on animal health but also indirectly through animal products on human health and through excreta on the environment. Due to increased awareness and concerns about animal health, due to increased incidence and severity of chronic non-communicable diseases in developed world that are linked to nutritional quality of (animal) food and due to .
